Use of muscarinic agonists in the treatment of Sjögren's syndrome

Clinical Immunology

Volumn 101, Issue 3, 2001, Pages 249-263

  Fox, Robert I ^a   Konttinen, Yrjö ^c   Fisher, Abraham ^b  

^a SCRIPPS MEMORIAL HOSPITAL   (United States)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^c Department of Medicine   (Finland)

Author keywords

Cevimeline; Muscarinic agonists; Muscarinic receptors; Pilocarpine; Sj gren's syndrome; Xerostomia

Indexed keywords

ACETYLCHOLINE; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; ARTIFICIAL TEAR; AZATHIOPRINE; CEVIMELINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; HYDROXYCHLOROQUINE; INTERLEUKIN 1; LEFLUNOMIDE; METALLOPROTEINASE; METHOTREXATE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; CYTOKINE RELEASE; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRY EYE; ENZYME RELEASE; HUMAN; NEUROENDOCRINOLOGY; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; SALIVARY GLAND; SALIVATION; SHORT SURVEY; SJOEGREN SYNDROME; THRUSH; XEROSTOMIA;

EID: 0035206846     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5128     Document Type: Review

References (164)

1. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca: Analysis of 618 patients with suspected Sjögren's syndrome
2. Criteria for the classification of Sjögren's syndrome
3. A unified theory of the role of the ocular surface in dry eye
4. Diagnosis of keratoconjunctivitis sicca
5. Cellulose acetate impressions of the ocular surface: Dry eye states
6. Major salivary gland function in primary Sjögren's syndrome and its relationship to clinical features
7. Importance of the lipid layer in human tear film stability and evaporation
8. Observation of precorneal tear film in patients with Sjögren's syndrome
9. Tear film: New concepts and implications for the management of the dry eye
10. Sjögren's syndrome: Pathogenesis and new approaches to therapy
11. Ocular side effects of selected systemic drugs
12. Salivary gland dysfunction
13. Diminished submandibular salivary flow in dementia of the Alzheimer type
14. The histopathology of Sjögren's syndrome in labial salivary gland biopsies
15. Salivary gland fluid secretion during aging
16. Is reduced salivary flow normal in old people?
17. Neurotransmitter control of secretion
18. Autonomic control of salivary secretion
19. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome
20. Vasoactive intestinal peptide which coexists with acetylcholine decreases acetylcholine turnover in mouse salivary glands
21. Distribution of vasoactive intestinal peptide (VIP) and its binding sites in labial salivary glands in Sjögren's syndrome and in normal controls
22. Identification and cellular localization of the components of the VIP signaling pathway in the lacrimal gland
23. Current issues in the diagnosis and treatment of Sjögren's syndrome
24. Expression of granzyme A in salivary gland biopsies from patients with primary Sjögren's syndrome
25. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome
26. Fas-induced apoptosis is a rare event in Sjögren's syndrome
27. Morphometric analysis of secretory glands in Sjögren's syndrome
28. Labial salivary gland biopsy in Sjögren's syndrome
29. Salivary and oral components of Sjögren's syndrome
30. Topology of innervation of labial salivary glands by protein gene product 9.5 and synaptophysin immunoreactive nerves in patients with Sjögren's syndrome
31. Peptide containing nerves labial salivary glands in Sjögren's syndrome
32. Conjunctival cytologic features of primary Sjögren's syndrome
33. Alterations of ocular surface gene expression in Sjögren's syndrome
34. The anatomy and innervation of lacrimal glands
35. Relationship between muscarinic receptor occupancy and response in rat parotid acinar cells
36. M1 agonists for the treatment of Alzheimer's disease: Novel properties and clinical update
37. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists
38. Progress and perspectives in new muscarinic agonists
39. Muscarinic agonists for the treatment of Alzheimer's disease: Progress and perspectives
40. Pharmacological evidence for the existence of different subtypes of muscarinic acetylcholine receptors for phosphoinositide hydrolysis in neonatal versus adult rat atria
41. Therapeutic opportunities for muscarinic receptors in the central nervous system
42. G protein coupling to M1 and M3 muscarinic receptors in sublingual glands
43. Both M1 and M3 receptors regulate exocrine secretion by mucous acini
44. Characterization of muscarinic acetylcholine receptors in human labial salivary glands
45. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain
46. Muscarinic receptor agonists in Alzheimer's disease
47. Structure-function analysis of muscarinic acetylcholine receptors
48. Muscarinic acetylcholine receptors: Structural basis of ligand binding and G protein coupling
49. Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis
50. Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands
51. Vasoactive intestinal polypeptide and the innervation of the human lacrimal gland
52. Regulation of mucous acinar exocrine secretion with age
53. Muscarinic cholinergic receptor subtypes in rat sublingual glands
54. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean
55. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 type
56. Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren's syndrome
57. Aquaporin water channel in salivary glands
58. Persistent increase in the amount of aquaporin-5 in the apical plasma membrane of rat parotid acinar cells induced by a muscarinic agonist SNI- 2011
59. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome
60. Human recombinant interleukin 1 beta suppresses acetylcholine release from rat myenteric plexus
61. Neuropathogenic actions of cytokines assessed in transgenic mice
62. Transforming growth factor-beta 1 and forskolin modulate gap junctional communication and cellular phenotype of cultured Schwann cells
63. Tumor necrosis factor-alpha and interleukin- 1 induce activation of MAP kinase and SAP kinase in human neuroma fibroblasts
64. Interferongamma-induced JAK2 and STAT1 signalling in a human salivary gland cell line
65. Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems
66. M1, M3 and M5 muscarinic receptors stimulate mitogen-activated protein kinase
67. G-protein signaling abnormalities mediated by CD95 in salivary epithelial cells
68. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome
69. A novel NOD-derived murine model of primary Sjögren's syndrome
70. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren's syndrome
71. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome
72. Treatment of Sjögren's syndrome
73. The 1998 Castroviejo Lecture: New strategies in the treatment of dry-eye states
74. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome
75. Punctal occlusion for the treatment of dry eye
76. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome
77. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca
78. Treatment of dry eye by autologous serum application in Sjögren's syndrome
79. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease: CsA Phase 3 Study Group
80. Xerostomia - Clinical evaluation and treatment in general practice
81. Sjögren's syndrome: Current therapies remain inadequate for a common disease
82. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjögren's syndrome
83. Oral pilocarpine: A review of its pharmacological properties and clinical potential in xerostomia
84. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren's syndrome: A randomized, placebo-controlled, fixed-dose, multicenter trial
85. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: A randomized, placebo-controlled, fixed-dose, multicenter trial
86. Salivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL/lpr mice
87. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats
88. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease
89. AF102B, a muscarinic M1 receptor agonist, mimics some effects of acetylcholine on neurons of rat hippocampus slices
90. Randomized, placebo-controlled trial of SNI-2011, a novel M3 muscarinic receptor agonist, for the treatment of Sjögren's syndrome
91. Evoxac capsules (cevimeline hydrochloride)
92. Approaches to the treatment of Sjögren's syndrome
93. Salagen tablets (pilocarpine hydrochloride)
94. Long-lasting salivation induced by a novel muscarinic receptor agonist SNI- 2011 in rats and dogs
95. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: Identification of a potential therapeutic agent for treatment of Sjögren's syndrome
96. M1 mnscarinic receptors block caspase activation by phosphoinositide 3-kinase- and MARK/ERK-independent pathways
97. Reduction of cerebrospinal fluid amyloid-beta after systemic administration of M1 muscarinic agonists
98. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease
99. Central nervous system (CNS) manifestations of primary Sjögren's syndrome: An overview
100. Central nervous system involvement in Sjögren's syndrome: Evidence from neuropsychological testing
101. Lymphocyte apoptosis and apoptosis-associated gene expression in Sjögren's syndrome
102. Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors
103. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome
104. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndrome
105. Excessive synthesis of matrix metalloproteinases in exocrine tissues of NOD mouse models for Sjögren's syndrome
106. Expression of metalloproteinase-2 (gelatinase A) in labial salivary glands of patients with Sjögren's syndrome with HTLV-I infection
107. Neuroendocrine manifestations in Sjögren's syndrome
108. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: A potential trigger for sialoadenitis of NOD mice
109. Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjögren's syndrome-like autoimmune exocrinopathy
110. Sjögren's syndrome: Genetic, environmental, clinical and therapeutic aspects
111. Salivary gland changes in the NOD mouse model for Sjögren's syndrome: Is there a non-immune genetic trigger?
112. Association of the glutathione S-transferase M1 homozygous null genotype with susceptibility to Sjögren's syndrome in Japanese individuals
113. Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome
114. Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice
115. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: An analytical evaluation
116. Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjögren's syndrome through fas-mediated apoptosis
117. Specific HLA-DQA and HLA-DRB1 alleles confer susceptibility to Sjögren's syndrome and autoantibody SS-B production
118. Expression and function of X chromosome-linked inhibitor of apoptosis protein in Sjögren's syndrome
119. A novel exogenous retrovirus sequence identified in humans
120. The expression of human endogenous retrovirus-3 in fetal cardiac tissue and antibodies in congenital heart block
121. Are endogenous retroviruses involved in human autoimmune disease?
122. Retroviruses in autoimmune liver disease: Genetic or environmental agents?
123. DRB1*15 and DRB1*03 extended haplotype interaction in primary Sjögren's syndrome genetic susceptibility
124. Androgen influence on lacrimal gland apoptosis, necrosis, and lymphocytic infiltration
125. Androgen stimulation of lacrimal gland function in mouse models of Sjögren's syndrome
126. T cell attractant chemokine expression initiates lacrimal gland destruction in nonobese diabetic mice
127. Pathogenesis and treatment of Sjögren's syndrome
128. Different forms of human vascular adhesion protein-1 (VAP-1) in blood vessels in vivo and in cultured endothelial cells: Implications for lymphocyte-endothelial cell adhesion models
129. The lymphoid system: Its normal architecture and potential for understanding the system through the study of lymphoproliferative diseases
130. + memory T cells to clear rotavirus infection
131. Cytokine expression in labial salivary glands from patients with primary Sjögren's syndrome
132. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome
133. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome
134. Cytokines in Sjögren's syndrome
135. Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjögren's syndrome
136. Cytokine expression in human labial minor salivary gland epithelial cells in health and disease
137. Bcl-2 family expression in salivary glands from patients with primary Sjögren's syndrome: Involvement of Bax in salivary gland destruction
138. Investigation of activation markers demonstrates overexpression of the secretory component on salivary glands epithelial cells in Sjögren's syndrome
139. The role of apoptosis in the initiation of the autoimmune response in Sjögren's syndrome
140. Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line
141. Chemokine expression and leucocyte infiltration in Sjögren's syndrome
142. Characterization of a cross-reactive idiotype on two human autoantibodies associated with systemic autoimmune disease
143. Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins
144. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome
145. Placental and fetal cardiac laminin are targets for cross-reacting autoantibodies from mothers of children with congenital heart block
146. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line
147. Quantitative analysis of apoptosis and bcl-2 in Sjögren's syndrome
148. Role of nitric oxide in Sjögren's syndrome
149. Alterations in the secretory response of non-obese diabetic (NOD) mice to muscarinic receptor stimulation
150. Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome
151. Oral pilocarpine HC1 stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome
152. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome
153. The use of oral pilocarpine in xerostomia and Sjögren's syndrome
154. Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome
155. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögren's syndrome
156. (+/-)-cis-2-methyl-spiro[1,3-oxathiolane-5,3′-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: The role of muscarinic acetylcholine receptors
157. Sjögren's syndrome: Treatment with antimalarial medications
158. Cyclosporin A (CyA) in primary Sjögren's syndrome: A double blind study
159. Methotrexate in primary Sjögren's syndrome
160. The uncertain role of immunosuppressive agents in Sjögren's syndrome
161. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis
162. Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide
163. sTNFbp prevents development of lymphoid infiltrates in the NOD mouse, a model for human Sjögren's syndrome
164. Neuroendocrine manifestations in Sjögren syndrome